FAIRFIELD, Conn., June 10, 2010 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (NYSE Amex:CTT) today announced the presentation of results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment. A three-hour discussion led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, at the American Society of Clinical Oncology (ASCO) Annual Meeting, cited results of the study. In a second venue at the ASCO meeting, Charles L. Loprinzi, M.D. Regis Professor of Breast Cancer Research in the Mayo Clinic's Division of Medical Oncology, presented Dr. Smith's research. The presentations highlighted the conclusion of the Massey Cancer Center study, that "Patient-specific cutaneous electrostimulation with the MC5-A Calmare device appears to dramatically reduce pain in refractory CIPN patients with no toxicity."
